SILVER SPRING, Md., July 25, 2016 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that during its upcoming shareholder call Chief Executive Officer Kenneth L. Waggoner will not only update shareholders on PharmaCyte’s clinical trial development program and respond to questions submitted by shareholders, he will discuss address PharmaCyte’s market opportunities beyond the United States and Europe. PharmaCyte appreciates the questions that have been submitted and, as of the time of this press release, the window for submitting questions has closed.
Mr. Waggoner commented, “We are looking forward to our first shareholder call. During the call I plan to provide information about PharmaCyte’s clinical development program and respond to the predominant questions submitted by shareholders. In addition, I will highlight developments with our partner Austrianova and how they have resulted in market opportunities for both PharmaCyte and Austrianova beyond those originally planned when we began collaborating together. We are excited about our future with Austrianova both here in the United States and abroad.”
The shareholder call is scheduled for:
| Date: | July 28, 2016 | ||
| Time: | 4:30 p.m. EDT | ||
| Telephone Number: | 605.562.0020 | ||
| Access Code: | 915-603-449 |
An audio replay will be available for two weeks. PharmaCyte will provide a telephone number and access code to listen to the recorded call the next day.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company developing therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed. PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. These encapsulated cells are implanted as close to the patient’s cancerous tumor as possible. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide comes in contact with the encapsulated cells they act as an artificial liver and activate the chemotherapy drug at the source of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in no side effects.
In addition to developing a novel therapy for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and insulin-dependent Type 2 diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient they will function as an “artificial pancreas” for purposes of insulin production.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend”, “plan” and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte’s ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Investor Relations: PharmaCyte Biotech, Inc. Investor Relations Department Telephone: 917.595.2856 Email: [email protected]
Source: PharmaCyte Biotech, Inc.
